Levels of Endocan in Umbilical Cord Blood Samples of Pregnant Females With Intrauterine Growth Retardation

NCT04630223 | Completed

• 1 other identifier: EndocanIUGR
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

As a proteoglycan secreted from endothelial cells, expression, and secretion of endocan increases in the endothelium of several tissues secondary to inflammation. It can be regarded as an indicator of endothelial damage. Besides, it is both a target and a modulator of the vascular endothelial growth factor (VEGF) signaling pathway. Considering its action mechanisms, it can provide information about angiogenesis, inflammation, and vascular permeability. It is known that intrauterine growth retardation mainly occurs as a result of endothelial dysfunction and abnormal angiogenesis in the placenta. In previous studies, maternal serum endocan levels have also been shown to be increased in cases of preeclampsia, which is mainly characterized by placental dysfunction.So, we hypothesize that there may be an association between endocan levels and intrauterine growth retardation.

Conditions

Intrauterine Retardation

Keywords

intrauterine growth retardation; umbilical cord blood; proteoglycans; pregnancy outcomes

Outcome Measures

Primary Outcomes (1)

• endocan in umbilical cord blood

  levels of endothelial cell specific molecule 1 (ng/ml) in umbilical cord blood

  just after delivery of fetus at clamping of umbilical cord

Study Arms (2)

intrauterine growth retardation

Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.

Diagnostic Test: endocan in umbilical cord blood

healthy fetuses

Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.

Diagnostic Test: endocan in umbilical cord blood

Interventions

endocan in umbilical cord blood DIAGNOSTIC_TEST

After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.

healthy fetuses; intrauterine growth retardation

Eligibility Criteria

• Age: 18 Years - 35 Years
• Gender Eligibility Details: female pregnants
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pregnant females attending outpatient clinics of obstetrics in a tertiary hospital.

You may qualify if:

• For "intrauterine growth retardation" group:
• consent to participate study
• detection of intrauterine growth retardation during follow up of pregnancy
• For "healthy fetuses" group:
• consent to participate study
• absence of intrauterine growth retardation during follow up of pregnancy

You may not qualify if:

• multiple pregnancy
• presence of major developmental anomalies of fetuses
• detection of chromosomal anomalies
• malnourished mothers
• vegetarian diet of mothers
• use of cigarette and alcohol during pregnancy
• previous history of stillbirths

Sponsors & Collaborators

• Van Bölge Eğitim ve Araştırma Hastanesi: lead

Study Sites (1)

Van Region Education and Training Hospital

Van, Turkey (Türkiye)

Location

Related Publications (3)

• Kucukbas GN, Kara O, Yuce D, Uygur D. Maternal plasma endocan levels in intrauterine growth restriction. J Matern Fetal Neonatal Med. 2022 Apr;35(7):1295-1300. doi: 10.1080/14767058.2020.1749591. Epub 2020 Apr 14.

  PMID: 32290736 RESULT

• Lan X, Liu Z. Circulating endocan and preeclampsia: a meta-analysis. Biosci Rep. 2020 Jan 31;40(1):BSR20193219. doi: 10.1042/BSR20193219.

  PMID: 31854443 RESULT

• Szpera-Gozdziewicz A, Kosicka K, Gozdziewicz T, Krzyscin M, Wirstlein P, Siemiatkowska A, Glowka F, Wender-Ozegowska E, Breborowicz GH. Maternal Serum Endocan Concentration in Pregnancies Complicated by Intrauterine Growth Restriction. Reprod Sci. 2019 Mar;26(3):370-376. doi: 10.1177/1933719118773480. Epub 2018 May 9.

  PMID: 29742984 RESULT

MeSH Terms

Conditions

Fetal Growth Retardation

Condition Hierarchy (Ancestors)

Fetal Diseases; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Growth Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, specialist on obstetrics and gynecology

Study Record Dates

• First Submitted: November 9, 2020
• First Posted: November 16, 2020
• Study Start: March 1, 2020
• Primary Completion: September 1, 2020
• Study Completion: September 30, 2020
• Last Updated: November 16, 2020

Record last verified: 2020-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)